Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02428712 · ClinicalTrials.gov registry record · Phase 1
A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
A Phase 1 study, sponsored by Fore Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
NCT02428712: Completed Phase 1 study, sponsored by Fore Biotherapeutics.
NCT02428712 is a Phase 1 study that has completed, run by Fore Biotherapeutics. The registered enrollment target is 113 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02428712, a Phase 1 study, has completed, sponsored by Fore Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
Study Summary
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.
Interventions
- DRUG FORE8394
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2015-04 |
| Est. Completion | 2024-07-12 |
| Phase | Phase 1 |
What the finished NCT02428712 record still lists
NCT02428712 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% higher).
The record links to 0 conditions, and to 1 intervention - of which FORE8394 is the first listed.
NCT02428712 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02428712 about?
NCT02428712 is a clinical study titled "A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors". The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.
What is the current status of trial NCT02428712?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2015-04. Estimated completion is 2024-07-12.
What interventions are being tested in trial NCT02428712?
The interventions under investigation include: FORE8394 (DRUG).
Who is sponsoring clinical trial NCT02428712?
This trial is sponsored by Fore Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02428712's enrollment target sits among peer trials
113 508th of 2000 higher than 1,493 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia